First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
J Greenhalgh, A Boland, V Bates… - Cochrane Database …, 2021 - cochranelibrary.com
Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non‐small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies
N Morikawa, Y Minegishi, A Inoue… - Expert opinion on …, 2015 - Taylor & Francis
Objective: To assess outcomes of elderly patients with advanced NSCLC harboring an
EGFR mutation treated with gefitinib, as well as safety and impact on quality of life (QoL) …
EGFR mutation treated with gefitinib, as well as safety and impact on quality of life (QoL) …
Emerging treatment for advanced lung cancer with EGFR mutation
C Inal, E Yilmaz, B Piperdi, R Perez-Soler… - Expert Opinion on …, 2015 - Taylor & Francis
Introduction: Lung cancer is the leading cause of cancer-related death worldwide. It is
usually diagnosed at advanced stage for which platinum-based chemotherapy had been the …
usually diagnosed at advanced stage for which platinum-based chemotherapy had been the …
Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC
A Somasundaram, MA Socinski… - Expert opinion on …, 2014 - Taylor & Francis
Introduction: The epidermal growth factor receptor (EGFR) is mutated in 15% of
adenocarcinomas of the lung. In addition, the anaplastic lymphoma kinase (ALK) is altered …
adenocarcinomas of the lung. In addition, the anaplastic lymphoma kinase (ALK) is altered …
Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non–Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup …
K Hotta, J Sasaki, S Saeki, N Takigawa, K Katsui… - Clinical Lung Cancer, 2016 - Elsevier
Herein, we describe an ongoing phase II trial in patients with locally advanced non–small-
cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR). Patients …
cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR). Patients …
[PDF][PDF] Synergistic Potential of EGFR Inhibi-tion and Thoracic Radiation for Locally Advanced Non-Small Cell Lung Cancer with Activating EGFR Muta-tion
Z Yang, W Zhang - Clin Onco, 2023 - clinicsofoncology.org
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) targeted therapy
has made great progress in lung cancer treatment recently, owe to its high response rate …
has made great progress in lung cancer treatment recently, owe to its high response rate …